Y-Intercept (HK)’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
Other funds holding BMY
AIM
FWIA
DLA
ETC
Y-Intercept (HK)'s BMY Position: Q2 2026 in Review
Y-Intercept (HK) reduced its Bristol-Myers Squibb (BMY) stake by 51% in Q2 2026, selling an estimated $2.82M and leaving 46,615 shares worth $2.69M. The position accounts for 0.05% of the portfolio, ranked #531.
Y-Intercept (HK) first reported a position in BMY in Q4 2020 and has held it in 17 quarters since. The position peaked at $9.2M in Q2 2025. 803 funds tracked by Wall St. Rank hold BMY as of Q2 2026.
- Y-Intercept (HK) held 46,615 shares of Bristol-Myers Squibb worth $2.69M as of Q2 2026.
- Y-Intercept (HK) sold 49,126 Bristol-Myers Squibb shares in Q2 2026, an estimated $2.82M.
- Bristol-Myers Squibb made up 0.05% of Y-Intercept (HK)'s portfolio in Q2 2026, its #531 holding.
- Y-Intercept (HK) first reported a position in Bristol-Myers Squibb in Q4 2020 and has held it in 17 quarters since.
- Y-Intercept (HK)'s Bristol-Myers Squibb position peaked at $9.2M in Q2 2025.
- 803 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2026.
Based on Y-Intercept (HK)'s 13F filing for Q2 2026, filed 14 Jul 2026.